|
Biomarkers for Pathways and Targets
Cancer Risk, Immunity, and Inflammation
Cell Death Mechanisms
Cellular Signaling
Co-Chairpersons: Alex Toker, Beth Israel Deaconess Medical Center, Boston, MA; and Dihua Yu, The University of Texas MD Anderson Cancer Center, Houston, TX
Critical Regulators of the Tumor Microenvironment
Drug Design and Lead Optimization
Epigenomics and Chromatin
Establishing Preclinical Rationale for Biological Therapeutic Agents
Functional Identification and Characterization of New Cancer Genes
Genetic Markers of Risk and Survival
Genomics of Pediatric Cancer
Identifying New Anticancer Drug Targets
Mechanisms of Drug Resistance
Metabolic Pathways Regulating Cancer
Metastasis Drivers: Models to Niches
microRNA Game: Of Mice and Humans, All for Patients
Molecular and Environmental Mechanisms of Carcinogenesis
Molecular Diagnostics for Personalized Cancer Therapy
Co-Chairpersons: John C. Byrd, The Ohio State University Comprehensive Cancer Center, Columbus, OH; and Manuel Hidalgo, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
Molecular Targets and Chemoresistance
Mouse Models of Human Cancer
Novel Drug Targets 2
Preventing Cancer by Targeting Inflammation, Stem Cells, and Death and Energy Pathways
Raf, Ras, Myc, and p53
Regulation of Cancer Stem Cells
Small-Molecule Inhibitors of Emerging Cancer Targets
Steroid Hormone Receptors in Breast and Prostate Cancer
Transcription Factors as Drivers and Therapeutic Targets in Cancer
Tumor Angiogenesis and Antiangiogenic Therapy
Tumor Biology
Tumor Immunotherapy: New Frontiers
|